设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 377|回复: 1

淋巴恶性肿瘤新免疫疗法

[复制链接]
发表于 2015-11-6 22:59:07 | 显示全部楼层 |阅读模式
淋巴恶性肿瘤新免疫疗法
摘要:靶向CD20单克隆抗体立普妥单抗在恶性淋巴瘤中的治疗成功,为开发免疫系统治疗提供了原则性的证据。自从FDA1997年批准了立普妥单抗,一些新的利用T细胞的能力靶向对抗癌细胞的策略也出现了。为了反映出这些新的免疫治疗途径的前景,FDA最近对三种不同机制的新治疗方案赋予了“重要技术突破”的称号。首先,嵌合抗原受体修饰的T细胞(CAR-T)治疗方案对成人和儿童复发或难治性急性淋巴白血病(ALL)的治疗展现出了希望。第二个,blinatumomab,双特异性T细胞衔接器(BiTE®)抗体药物,现在被批准用于治疗成人费城染色体缺失型复发和/或者难治性记性B淋巴细胞白血病。最后一个,是单克隆抗体立普妥,针对PD-1免疫检查点受体具有高亲和力,用于治疗霍奇金淋巴瘤治疗后失败的自体干细胞移植和药物brentuximab vedotin治疗。在这里,我们回顾了这三种不同的免疫治疗平台的背景和发展,了解每种治疗方案的作用机制来促进了科学的提高,并评估目前的临床知识,其疗效和安全性。我们还讨论了将来的治疗策略,通过加强改造、生物标志物的选择、以机制为基础的联合治疗方案来提高这些免疫疗方法。
Novel immunotherapies in lymphoid malignancies
Abstract
The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of T cells to target cancer cells have emerged. Reflecting on the promising clinical efficacy of these novel immunotherapy approaches, the FDA has recently granted 'breakthrough' designation to three novel treatments with distinct mechanisms. First, chimeric antigen receptor (CAR)-T-cell therapy is promising for the treatment of adult and paediatric relapsed and/or refractory acute lymphoblastic leukaemia (ALL). Second, blinatumomab, a bispecific T-cell engager (BiTE®) antibody, is now approved for the treatment of adults with Philadelphia-chromosome-negative relapsed and/or refractory B-precursor ALL. Finally, the monoclonal antibody nivolumab, which targets the PD-1 immune-checkpoint receptor with high affinity, is used for the treatment of Hodgkin lymphoma following treatment failure with autologous-stem-cell transplantation and brentuximab vedotin. Herein, we review the background and development of these three distinct immunotherapy platforms, address the scientific advances in understanding the mechanism of action of each therapy, and assess the current clinical knowledge of their efficacy and safety. We also discuss future strategies to improve these immunotherapies through enhanced engineering, biomarker selection, and mechanism-based combination regimens.

 楼主| 发表于 2015-11-8 22:46:31 | 显示全部楼层
爱康得生物医学技术(苏州)有限公司,专注免疫治疗。
更多资讯,请关注http://www.icartab.com.cn/company_overview.html
您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-22 22:18 , Processed in 0.095253 second(s), 19 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表